GLP‑1/GIP add‑on therapy stabilizes Ramadan dysglycaemia

Key Takeaways

• Adding semaglutide or tirzepatide to insulin regimens doubles time‑in‑range during Ramadan.
• Post‑iftar glucose spikes drop by about 61 % with GLP‑1/GIP add‑on therapy.
• Tightened glycaemic control occurs without raising hypoglycaemia risk.

What does continuous glucose monitoring show about Ramadan dysglycaemia?

Ramadan dysglycaemia refers to sharp blood sugar swings during fasting. Continuous glucose monitoring data reveal that insulin users experience significant improvement when doctors add semaglutide (a GLP‑1 receptor agonist) or tirzepatide (a dual GLP‑1/GIP agonist) to their regimen. A study of adults with insulin‑treated type 2 diabetes compared basal–bolus insulin alone against insulin plus semaglutide or tirzepatide, measuring glucose patterns before and during Ramadan 2025. Patients on add‑on therapy achieved time in range of 74.4 % versus 36.8 % for insulin alone (p=0.007). Glucose management indicator fell to 6.9 % versus 8.3 % (p=0.004). Post‑iftar area under the curve dropped by about 61 %—from 260,578 to 102,014 mg/dL·min—without raising hypoglycaemia risks or causing treatment discontinuation during Ramadan (sciencedirect.com).

Why do semaglutide or tirzepatide blunt post‑iftar glucose spikes?

Both drugs slow gastric emptying, suppress glucagon, and trigger insulin release when blood glucose climbs—all in glucose‑dependent ways that spare the body when sugar is already low. Continuous glucose monitoring data show these mechanisms flatten the rapid post‑iftar rises that typically occur in the 4‑hour window after breaking fast (researchgate.net).

Are there safety concerns with add‑on GLP‑1/GIP therapy during fasting?

The CGM‑based study reported no severe hypoglycaemia in either group. Patients on add‑on therapy completed Ramadan without treatment discontinuation, suggesting good tolerability in real‑world insulin‑treated patients during fasting (sciencedirect.com).

FAQ

What is Ramadan dysglycaemia?

Ramadan dysglycaemia refers to sharp blood sugar fluctuations in people with diabetes during Ramadan fasting, especially after iftar.

How does GLP‑1/GIP add‑on therapy help insulin‑treated patients during Ramadan?

Adding semaglutide or tirzepatide improves time in range, lowers glucose management indicator, and reduces post‑iftar spikes without increasing hypoglycaemia risk.

How much do post‑iftar glucose spikes drop with therapy?

Post‑iftar incremental area under the curve drops by about 61 % when GLP‑1/GIP therapy is added to insulin based on CGM data.

Does add‑on therapy increase hypoglycaemia risk during Ramadan?

No. The study found no severe hypoglycaemia and good tolerability with no treatment discontinuations during Ramadan.

What does CGM stand for and what does it show?

CGM stands for continuous glucose monitoring. It tracks interstitial glucose trends throughout fasting and feeding periods to assess swings like Ramadan dysglycaemia.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs and fasting is not right for everyone — talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.